Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer

NCT04725994 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

87

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric Cancer

Interventions

DRUG: IDX-1197+XELOX
DRUG: IDX-1197+Irinotecan

Sponsor

Idience Co., Ltd.